Wire · opportunities
FDA Expands Mavacamten for Children with oHCM
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 October 2026 · Fusion42 review
The FDA has expanded approval of mavacamten to include pediatric patients aged 12 to 18 with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), offering a new mechanism-based therapy option beyond traditional treatments. The approval is supported by the SCOUT-HCM trial showing significant symptom and functional improvements, albeit under strict REMS safety monitoring and pharmacy oversight.
This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 30 Sep 2026 and 2 Oct 2026.
◆ ◆ The Wire takeaway
You must now handle complex FDA REMS oversight for a pediatric cardiac drug that opens new patient segments but demands strict monitoring and adherence programs. Pharmacists gain a pivotal role helping families overcome geographic and procedural barriers to advanced treatment.
◆ Coverage
3 sources · first reported 30 Sep 2026 · latest 2 Oct 2026
◆ Related on Wire
◆ Topics